Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 53 No. 3
PSYCHOPHARMACOLOGY BULLETIN

VOL 53 No. 3

Articles in This Issue

ORIGINAL RESEARCH

Association Between Symptom Severity and Medication Adherence in Adolescents with Bipolar Disorder Demonstrating Suboptimal Adherence

Martha Sajatovic, Jennifer B Levin, Avani Modi, Molly McVoy, Larry F Forthun, Raechel Cooley, Jessica Black, Carla Conroy, Kaylee Sarna, Farren B Briggs, Melissa DelBello
Objective While medication non-adherence is common in bipolar disorder (BD), few studies have specifically assessed non-adherent BD adolescents and young adults (AYAs). This analysis, using screening and baseline data from an ongoing randomized controlled trial,...
Pages 8-21 Read Article
REVIEW ARTICLE

On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression

Vincent Van den Eynde, Gordon Parker, Henricus G. Ruhé, Tom K. Birkenhäger, Lila Godet, Edward Shorter, Peter Kenneth Gillman
The first monoamine oxidase inhibitors (MAOIs) used for the treatment of depression in the 1950–60s were credited with treating severe melancholic depression (MeD) successfully and greatly reducing the need for electroconvulsive therapy (ECT). Following the...
Pages 35-54 Read Article
COMPLICATED CASE HISTORY

Cannabis Pen-Induced Psychosis in a First-Time Adolescent User

Patrick J Beck, Abhishek Reddy
Cannabis is a widely used illicit substance that is historically consumed via smoking, but alternative methods of cannabis consumption have been growing in popularity over the past several decades. One such modality is vaporization, which...
Pages 61-65 Read Article
COMPLICATED CASE HISTORY

Takotsubo Cardiomyopathy Related to Duloxetine-Atomoxetine Combination in an Adolescent with ADHD and Comorbid GAD

Ahmed Naguy, Bibi Alamiri
Authors report on an interesting case of a teenager with attention-deficit/hyperactivity disorder and comorbid generalized anxiety disorder, who developed takotsubo cardiomyopathy subsequent to pharmacokinetic and pharmacodynamic interactions between atomoxetine, a selective norepinephrine reuptake inhibitor, and...
Pages 66-68 Read Article